Modality
mAb
MOA
TROP-2 ADC
Target
RET
Pathway
Amyloid
SMABladder CaMigraine
Development Pipeline
Preclinical
~May 2013
→ ~Aug 2014
Phase 1
~Nov 2014
→ ~Feb 2016
Phase 2
~May 2016
→ ~Aug 2017
Phase 3
Nov 2017
→ Mar 2031
Phase 3Current
NCT07331391
1,648 pts·Migraine
2017-11→2030-11·Completed
NCT04200084
2,626 pts·Bladder Ca
2019-08→2031-03·Recruiting
NCT05123011
1,887 pts·Migraine
2025-08→2026-03·Active
6,161 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-03-231w agoPh3 Readout· Migraine
2030-11-244.7y awayPh3 Readout· Migraine
2031-03-124.9y awayPh3 Readout· Bladder Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Complet…
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2026-03-23 · 1w ago
Migraine
Ph3 Readout
2030-11-24 · 4.7y away
Migraine
Ph3 Readout
2031-03-12 · 4.9y away
Bladder Ca
RecruitingActiveCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07331391 | Phase 3 | Migraine | Completed | 1648 | LiverFat |
| NCT04200084 | Phase 3 | Bladder Ca | Recruiting | 2626 | BodyWt |
| NCT05123011 | Phase 3 | Migraine | Active | 1887 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |